作者
Ignace Vergote, Corneel Coens, Matthew Nankivell, Gunnar B Kristensen, Mahesh KB Parmar, Tom Ehlen, Gordon C Jayson, Nick Johnson, Ann Marie Swart, René Verheijen, W Glenn McCluggage, Tim Perren, Pierluigi Benedetti Panici, Gemma Kenter, Antonio Casado, Cesar Mendiola, Gavin Stuart, Nick S Reed, Sean Kehoe, Claes Tropé, Stephen Dobbs, Sharadah Essapen, P Hoskins, John Green, E Gilby, M Van Baal, Jeremy Twigg, Maria EL Van Der Burg, Keith Godfrey, Angel J Lacave, R Angioli, Rahul Nath, Kirk Chin, Charles Redman, R Lotocki, Adeola Olaitan, B Mosgaard, G Rustin, Thomas Ind, Mojca Persic, Martin Hogg, J Van Der Velden, J Ledermann, Peter Sykes Peter Sykes, Krishnawam Madhavan, P Kannisto, Vicky Hird, A Evans, P Gauthier, DJ Cruickshank, PB Ottevanger, Sheila Pearson, Henry Kitchener, Marcia Hall, P Bessette, S Pecorelli, E Gerdin, Tito Lopes, Andrew Fish, Clare Barlow, K Van Eygen, A Floquet, B Tholander, N Gul, Robert Gornall, David Luesley, Philip Kirwan, Paul Symonds, Richard Henry, David Poole, Ian McNeish, Mark Hocking, Al Sammaraie, P Speiser, E Leblanc, JA Green, CF De Oliveira, R Grimshaw, P Zola, David Parkin, Martin Lamb, Anne Hong, Alan Gillespie, Abdel Hamid, Ahmed Ahmed, M Plante, B De Valk, A Nordin, Andrew Clamp, David Perez, Graham Dark Graham Dark, Michelle Ferguson, Carol MacGregor, Geraldine Skailes, Rachel Jones, G Cawdell, Simon Leeson, L Elit, C Dittrich, W Gotlieb, John Cullimore, Barbara Crosse, Paul Ridley, Anthony Head, Joaquin Nieto, Saif Awwad, Dirk Brinkmann, Damian Eustace, Andrew Hindley, D Katsaros, C Popadiuk, Tome Kristeller, C Redman, S Chan, C Marth, Dennis Yiannakis, Kate Lankaster, Gareth Beynon, Anwar Suhail, Fernando Indrajit, Mary Quigley, Olu Adeyemi, Fiona Lofts, Orla McNally, Amanda Tristam, Martin Lee, R Counsell, N Gleeson, A Papadopoulos, T Maggino, A Honkoop, P Ghatage, JB Vermorken, J De Greve, K Boman, E Petru, F Amant
发表日期
2018/12/1
期刊
The Lancet Oncology
卷号
19
期号
12
页码范围
1680-1687
出版商
Elsevier
简介
Background
Individual patient data from two randomised trials comparing neoadjuvant chemotherapy with upfront debulking surgery in advanced tubo-ovarian cancer were analysed to examine long-term outcomes for patients and to identify any preferable therapeutic approaches for subgroup populations.
Methods
We did a per-protocol pooled analysis of individual patient data from the European Organisation for Research and Treatment of Cancer (EORTC) 55971 trial (NCT00003636) and the Medical Research Council Chemotherapy Or Upfront Surgery (CHORUS) trial (ISRCTN74802813). In the EORTC trial, eligible women had biopsy-proven International Federation of Gynecology and Obstetrics (FIGO) stage IIIC or IV invasive epithelial tubo-ovarian carcinoma. In the CHORUS trial, inclusion criteria were similar to those of the EORTC trial, and women with apparent FIGO stage IIIA and IIIB disease were also …
学术搜索中的文章
I Vergote, C Coens, M Nankivell, GB Kristensen… - The Lancet Oncology, 2018